2024
Outcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers
Zakeri K, Shang T, Yu Y, Chen L, Shamseddine A, Kang J, Tsai C, Sherman E, Wong R, McBride S, Gelblum D, Riaz N, Lee N. Outcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e807. DOI: 10.1016/j.ijrobp.2024.07.1772.Peer-Reviewed Original ResearchP16-negative oropharyngeal squamous cell carcinomaNegative oropharyngeal squamous cell carcinomasOropharyngeal squamous cell carcinomaDistant recurrenceSquamous cell carcinomaNodal recurrenceRadiotherapy doseLocoregional recurrenceP16 statusCell carcinomaHypopharynx cancerP16-negative oropharyngeal cancerHead and neck cancer patientsRadiation doseElective nodal volumesP16-negative diseaseNode-positive diseaseDecrease treatment toxicityNeck cancer patientsPrimary outcome measureConcurrent cetuximabConcurrent chemotherapyLocoregional controlMedian followNodal diseaseLong-Term Results of External Beam Radiation Therapy (RT) with or without Concurrent Chemotherapy in Loco-Regionally Advanced or Recurrent Differentiated Thyroid Cancer (DTC)
Choi J, Sherman E, Youssef I, Kang J, Zakeri K, Yu Y, Chen L, Shamseddine A, McBride S, Riaz N, Hung T, Wong W, Michel L, Dunn L, Ho A, Tuttle R, Morris L, Shaha A, Wong R, Lee N. Long-Term Results of External Beam Radiation Therapy (RT) with or without Concurrent Chemotherapy in Loco-Regionally Advanced or Recurrent Differentiated Thyroid Cancer (DTC). International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e743-e744. DOI: 10.1016/j.ijrobp.2024.07.1633.Peer-Reviewed Original ResearchResults of external beam radiation therapyLocoregional controlRadioactive iodine therapyOverall survivalMultivariate analysisIodine therapyAdvanced diseaseBackward stepwise Cox regressionExternal beam radiation therapyRecurrent differentiated thyroid cancerProton beam RTBeam radiation therapyIntensity-modulated RTSingle-institution experienceTreated with RTMedian follow-upKaplan-Meier methodDay of RTStepwise Cox regressionGroup of patientsLong-term resultsBeam RTLate toxicityNon-medullaryConcurrent chemotherapy
2022
Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy
Youssef I, Yoon J, Mohamed N, Zakeri K, Press R, Yu Y, Kang J, Wong R, Tuttle R, Shaha A, Sherman E, Lee N. Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy. International Journal Of Particle Therapy 2022, 9: 20-30. PMID: 36060412, PMCID: PMC9415751, DOI: 10.14338/ijpt-22-00005.1.Peer-Reviewed Original ResearchPercent of patientsLocal-regional recurrenceThyroid cancerRadiation therapyGross diseaseOverall survivalPercutaneous endoscopic gastrostomy tubeProton therapyProton beam radiation therapyAcute grade 3Central neck compartmentFavorable therapeutic ratioIntensity-modulated radiation therapyBeam radiation therapyProton beam therapyConcurrent chemotherapyPalliative radiationUnresectable diseaseAdjuvant radiationDefinitive radiationT4 diseaseMetastatic diseaseNeck compartmentRegional recurrenceUpper mediastinum
2021
The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer.
Lee N, Sherman E, Schöder H, McBride S, Yu Y, Kang J, Tsai C, Gelblum D, Boyle J, Singh B, Cohen M, Cracchiolo J, Ganly I, Dunn L, Kriplani A, Fetten J, Michel L, Wong R, Pfister D, Riaz N. The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer. Journal Of Clinical Oncology 2021, 39: 6019-6019. DOI: 10.1200/jco.2021.39.15_suppl.6019.Peer-Reviewed Original ResearchPositron emission tomographyGrade 1Locoregional controlNodal diseaseOropharyngeal carcinomaOPC patientsGrade 2Primary siteGrade 3 adverse eventsWeight lossDe-escalated patientsGross nodal diseaseRecurrent nodal diseaseResolution of hypoxiaSuccessful salvage surgeryExcellent locoregional controlOverall survival rateSpecific treatment responsesPatient-specific treatment responsesConcurrent chemotherapyDefinitive doseMucositis ratesAdditional therapySalvage surgeryAdverse events